Navigation Links
Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome
Date:4/11/2012

WICHITA, Kan., April 11, 2012 /PRNewswire-USNewswire/ -- Riordan Clinic scientists Dr. Nina Mikirova, Dr. Joseph Casciari, and Dr. Ronald Hunninghake have patented a new technology that may help doctors determine the severity of fatigue in their patients.  The research, recently published in the January/February issue of the journal, Alternative Therapies, is entitled "The Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome by Serum Fluorescence Emission." 

Chronic fatigue syndrome (CFS) is characterized by long-lasting disabling fatigue. It includes non-specific symptoms such as weakness, malaise, subjective fever, sore throat, lymph node pain, and decreased memory. There are no conclusive diagnostic tests for CFS.  Since the underlying mechanism for CFS is not known, finding reliable biomarkers for diagnosing are important. 

The purpose of this study was to examine the use of serum nicotinamide adenine dinucleotide (NAD(P)H) levels as a metabolic marker of fatigue state and alterations in metabolism and homeostasis in CFS patients. 

The Riordan Clinic scientists have developed a method of determining NAD(P)H levels based on fluorescence emission of serum at 450 nm. Serum NAD(P)H concentrations were  compared for subjects with CFS and healthy controls.  NAD(P)H concentrations in the serum of CFS subjects averaged 8.0 +/- 1.4 (SD) uM while those in healthy controls averaged 10.8 +/- 0.8 (SD) uM, a statistically significant difference (p < 0.001). 

The sensitivity (detection of positives) and specificity (non-detection of negatives) of the test in matching CFS patients to control subjects at NAD(P)H cut-off of 9.5 uM were 0.73 and 0.98.   

The researchers also compared NAD(P)H concentrations to other endocrine and metabolic parameters. A factor analysis, based on the correlation matrix between all variables, demonstrated that the best correlations were between the NAD(P)H, serum coenzyme Q10 and urine pyrroles.

As coenzyme Q10 is the component of a complex series of reactions that occur within mitochondria, the function of Q10 ultimately is linked to the generation of energy within the cells.  The correlation between the lower level of coenzyme Q10 and lower NAD(P)H signals for patients with CFS suggests lower bioenergetics for these subjects.

An inverse correlation was found between the level of serum emission and the level of pyrroles in urine. The pyrroles are often elevated in patients with mental illness. This molecule is well known for bio-toxicity and is associated with emotional stress.

As a result of the study, researchers proposed that fatigue level and metabolic slowdown in CFS patients can be evaluated and monitored by serum NAD(P)H concentration measurements.

The measurement of the fluorescence of reduced nicotinamide adenine dinucleotide in serum provides a non-invasive assay to estimate metabolism and fatigue levels in CFS patients.  Following patient NAD(P)H levels over time may aid in selecting therapeutic strategies and monitoring treatment outcome.

To read this and other articles written by Riordan Clinic researchers, go to http://www.riordanclinic.org/research/journal-articles.shtml.

The Riordan Clinic is a progressive nutrition-based medical clinic located in Wichita, Kansas. For 36 years, the Riordan Clinic has integrated lifestyle and nutrition to help patients find the underlying causes of their illness. Since the inception in 1975, the mission has been clear and unwavering to "…stimulate an epidemic of health."

If you would like more information about this topic, please call Tiffany Hurley at (316) 682-3100 or email at thurley@riordanclinic.org.

 

 

 

 


'/>"/>
SOURCE Riordan Clinic
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The ABC Clinical Guide to Herbs Now Available Online
2. First targeted and programmable nanomedicine to show clinical antitumor effects published
3. inVentiv Health Completes Acquisition of Kforce Clinical Research
4. Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association
5. New imaging technique moves from lab to clinic
6. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
7. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
8. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
9. Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference
10. Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities
11. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... ... Okyanos Cell Therapy has announced Tallahassee, FL will be the next destination ... Therapy: The Next Phase in the Evolution of Medicine.” As the Bahamas’ first fully ... Act, Okyanos maintains a mission to help “no-option” patients and those with serious, ...
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the launch ... held on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO ... Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a unique ...
(Date:3/22/2017)... ... ... March 22, 2017...Council for Agricultural Science and Technology, Ames, Iowa. , Many ... smart, sustainable ways. Humans depend on plants for food, feed, fiber, and fuel—as well ... is the first in a series that connects science and technology to agriculture, and ...
(Date:3/22/2017)... 2017   Invitae Corporation (NYSE: NVTA), ... today announced the availability of a new genetic ... Atrophy (SMA) , a neuromuscular disease that is ... infants as well as a significant cause of ... announced during the American College of Medical Genetics ...
Breaking Biology Technology:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant ... At PTE ... March, Materna will present its complete end-to-end passenger journey, ... real benefit for passengers. To accelerate the whole passenger handling ... solutions to take passengers through the complete integrated process with ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
Breaking Biology News(10 mins):